Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Immune Checkpoint Inhibitors: Trends and Market Dynamics | Special Topics | G7 – 2020
Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of…
Dry and Wet Age-Related Macular Degeneration | Special Topics | Beovu: Nine Months Postlaunch for Wet AMD | US | 2020
Novartis’s Beovu (brolucizumab-dbll) was the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United…